Swiss drug major Novartis' Rasilez HCT (aliskiren and hydrochlorothiazide), a single-pill combination of two high blood pressure medicines - the first-in-class direct renin inhibitor Rasilez (aliskiren) and the diuretic hydrochlorothiazide - has been approved by Swissmedic as a new treatment for high blood pressure. The first new type of blood pressure medicine in over a decade, Rasilez, known as Tekturna in the USA, provides effective blood pressure lowering that lasts beyond 24 hours, Novartis noted, adding that HCT is one of the most commonly-used diuretics in the treatment of hypertension, which affects nearly one in four adults worldwide. The Basel-headquartered firm said it expects Europe-wide approval early next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze